| Bioactivity | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1]. |
| Invitro | Leronlimab (1-140 mg/mL) 结合 CCR5 阳性细胞高达 98%[1]。Leronlimab (80-1750 μg/mL) 阻断 MDA-MB-231 细胞中 CCL5，CCL3 和 CCL4 诱导的钙反应[1]。Leronlimab (175 和 350 mg/mL) 阻断 MDA-MB-231 细胞侵袭[1]。Leronlimab (10 μg/mL；72 小时) 增强 doxorubicin 对 MDA-MB-231 细胞的细胞毒性[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况[1]。 Animal Model: |
| Name | Leronlimab |
| CAS | 674782-26-4 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11. |